2. Search Result
Search Result
Results for "

neck cancer

" in MedChemExpress (MCE) Product Catalog:

46

Inhibitors & Agonists

1

Biochemical Assay Reagents

4

Peptides

10

Inhibitory Antibodies

7

Natural
Products

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16488
    Temoporfin
    10+ Cited Publications

    m-THPC; KW2345

    		 Reactive Oxygen Species (ROS) Cancer
    Temoporfin (m-THPC), a reduced porphyrin, is a potent second-generation photosensitizer. Temoporfin can be used in the research of photodynamic therapy (PDT) for head and neck cancers .
    Temoporfin
  • HY-113168
    Butyrylcarnitine
    1 Publications Verification

    		 Endogenous Metabolite Cardiovascular Disease Metabolic Disease Cancer
    Butyrylcarnitine is an endogenous metabolite found in plasma. Elevated levels of Butyrylcarnitine are closely associated with abnormalities in lipid and energy metabolism. Butyrylcarnitine can serve as a diagnostic and prognostic indicator for certain diseases, such as heart failure and head and neck cancer .
    Butyrylcarnitine
  • HY-P99406
    Petosemtamab

    MCLA 158

    		 EGFR Cancer
    Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .
    Petosemtamab
  • HY-169581
    DIM-C-pPhtBu

    		Reactive Oxygen Species (ROS) Mitosis Cancer
    DIM-C-pPhtBu is an orally active endoplasmic reticulum stress activator. DIM-C-pPhtBu induces mitochondrial and lysosome dysfunction, excessive mitosis, ROS production, and unfolded protein response-mediated cell death in neck cancer cells. DIM-C-pPhtBu has antitumor activity .
    DIM-C-pPhtBu
  • HY-169730
    Wnt pathway inhibitor 5

    		Wnt Cancer
    Wnt pathway inhibitor 5 (Compound 28) is wnt pathway inhibitor, with an IC50 value of < 0.003 μΜ. Wnt pathway inhibitor 5 inhibits many cancers, including ovarian teratocarcinoma cancer, breast cancer, osteosarcoma, head and neck squamous carcinoma .
    Wnt pathway inhibitor 5
  • HY-P99500
    Cetuximab sarotalocan

    RM-1929; Cetuximab-IRDye-700DX

    		 EGFR Cancer
    Cetuximab sarotalocan (RM-1929) is an IRdye700DX (near-infrared photosensitizing dye) conjugate of Cetuximab (anti-EGFR monoclonal antibody). Cetuximab sarotalocan can be used for head and neck cancers research .
    Cetuximab sarotalocan
  • HY-P991342
    CQY684

    PCA062 antibody

    		 Cadherin Cancer
    CQY684 (PCA062 antibody) is a human monoclonal antibody (mAb) targeting CDH3/P-cadherin. CQY684 stabilizes the X-dimer of P-cadherin, promoting its endocytosis and directing it to lysosomal degradation. CQY684 can be used in Breast, esophageal, and head and neck cancers research .
    CQY684
  • HY-16488R
    Temoporfin (Standard)

    		Reactive Oxygen Species (ROS) Cancer
    Temoporfin (Standard) is the analytical standard of Temoporfin. This product is intended for research and analytical applications. Temoporfin (m-THPC), a reduced porphyrin, is a potent second-generation photosensitizer. Temoporfin can be used in the research of photodynamic therapy (PDT) for head and neck cancers .
    Temoporfin (Standard)
  • HY-147802
    EGFR-IN-59

    		EGFR Apoptosis Cancer
    EGFR-IN-59 (Compound 8c) is a EGFR inhibitor (IC50=190 nM) and apoptosis inducer. EGFR-IN-59 exhibits cytotoxicity against non-small lung cancer cell lines (A549) and normal lung fibroblasts (WI38) with IC50s of 8.62 and 52.6 µM, respectively. EGFR-IN-59 can be used for the research of various cancers such as non-small cell lung cancer (NSCLC), head and neck cancer, breast cancer and colorectal cancer .
    EGFR-IN-59
  • HY-175164
    SVC112

    		Apoptosis c-Myc Cancer
    SVC112 is a translation elongation inhibitor that prevents the cyclic dissociation of EF2 from the ribosome, thereby inhibiting the elongation step of translation. SVC112 shows activity in growth inhibition among cancer cell lines of various origins (acute myeloid leukemia (AML), multiple myeloma (Myeloma), colorectal cancer (CRC), and head and neck squamous cell carcinoma (HNSCC)). SVC112 preferentially impedes ribosomal processing of mRNAs, and decreaseds CSC-related proteins including Myc and Sox2. SVC112 induces apoptosis in hematologic cancer cell lines, while phosphorylation of c-Myc correlates with sensitivity to SVC112 in colorectal cancer cell lines. SVC112 inactivates HNSCC stem cells in vitro and prevents the regrowth of HNSCC tumor xenografts in mice. SVC112 can be used for the study of HNSCC .
    SVC112
  • HY-122949
    Momordicine I

    		Apoptosis Autophagy DGK Mitochondrial Metabolism NO Synthase PI3K Akt Interleukin Related Src AMPK mTOR NF-κB c-Met/HGFR STAT Keap1-Nrf2 Reactive Oxygen Species (ROS) Oxidative Phosphorylation Endogenous Metabolite Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Momordicine I is a cucurbitane-type triterpenoids. Momordicine I suppresses glioma growth by promoting apoptosis and impairing mitochondrial oxidative phosphorylation. Momordicine I inhibits glycolysis, lipid metabolism, induces autophagy in HNC cells to suppress head and neck cancer growth. Momordicine I alleviates isoproterenol-induced cardiomyocyte hypertrophy through suppression of PLA2G6 and DGK-ζ. Momordicine I exerts its cardiovascular benefits by upregulating nitric oxide, inhibiting the activity of angiotensin-converting enzyme (ACE), activating the PI3K/Akt pathway, reducing oxidative stress and inflammation. Momordicine I inhibits AKT1, IL-6, and SRC, suggesting its potential application in type 2 diabetes .
    Momordicine I
  • HY-108345
    Bleomycin

    		Antibiotic Cancer
    Bleomycin is a glycopeptide antibiotic. Bleomycin has potent antitumour activities against a range of lymphomas, head and neck cancers and germ-cell tumours. Bleomycin can be used for the research of cancer and chemotherapy .
    Bleomycin
  • HY-16349
    Nimorazole
    1 Publications Verification

    K-1900

    		 Parasite Antibiotic Infection Cancer
    Nimorazole (K-1900), a 2-nitroimidazole, is a hypoxic cell-radiation sensitizer. Nimorazole has anti-infective and anti-protozoal against trichomoniasis. Nimorazole has the potential for head and neck cancer .
    Nimorazole
  • HY-13617
    Edatrexate

    CGP 30694

    		 Antifolate Cancer
    Edatrexate (CGP 30694), as known as 10-Ethyl-10-deazaaminopterin, is Methotrexate (HY-14519) analog, exhibits antitumor activity against MTX-resistant tumors. Edatrexate is an antifolate antimetabolite, can be used for reasearch of non-small-cell lung cancer, breast cancer, non-Hodgkin's lymphoma, and cancer of the head and neck .
    Edatrexate
  • HY-E70188
    N-Acetylgalactosamine-6-Sulfatase

    EC:3.1.6.4; GALNS

    		 Biochemical Assay Reagents Cancer
    N-Acetylgalactosamine-6-Sulfatase (GALNS) is a potential general biomarker for multiple malignancies (such as lung cancer, breast cancer, head and neck cancer, etc.). N-Acetylgalactosamine-6-Sulfatase deficiency causes mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome. N-Acetylgalactosamine-6-Sulfatase can be used in MPS IVA as well as cancer research .
    N-Acetylgalactosamine-6-Sulfatase
  • HY-P991244
    REGN-1400

    		EGFR Cancer
    REGN-1400 is a humanized monoclonal antibody inhibitor targeting ErbB3. REGN-1400 reduces tumor cell proliferation by inhibiting ErbB3 and blocking related signaling pathways. REGN-1400 is promising for research of solid tumors such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and squamous cell carcinoma of the head and neck (SCCHN) .
    REGN-1400
  • HY-16349R
    Nimorazole (Standard)

    K-1900 (Standard)

    		 Reference Standards Parasite Antibiotic Infection Cancer
    Nimorazole (Standard) is the analytical standard of Nimorazole. This product is intended for research and analytical applications. Nimorazole (K-1900), a 2-nitroimidazole, is a hypoxic cell-radiation sensitizer. Nimorazole has anti-infective and anti-protozoal against trichomoniasis. Nimorazole has the potential for head and neck cancer .
    Nimorazole (Standard)
  • HY-15673
    KP372-1
    2 Publications Verification

    		 Quinone Reductase Akt Reactive Oxygen Species (ROS) Apoptosis Cancer
    KP372-1 is an Akt inhibitor that inhibits proliferation and induces apoptosis and anoikis. KP372-1 is also an NQO1 redox cycling agent that causes DNA damage (including DNA breakage) by generating ROS. KP372-1 can be used in cancer research (such as head and neck squamous cell carcinoma (HNSCC) and pancreatic cancer) .
    KP372-1
  • HY-148664
    eIF4E-IN-4

    		Eukaryotic Initiation Factor (eIF) Cancer
    eIF4E-IN-4 (Compound 33) is a selective inhibitor of eukaryotic initiation factor 4E (eIF4E) with biochemical activity value of 95 nM. eIF4E-IN-4 inhibits cap-dependent mRNA translation with an IC50 value of 2.5 μM. eIF4E-IN-4 can be used for breast cancer, colon cancer, and head and neck cancer study .
    eIF4E-IN-4
  • HY-152007S
    Butyrylcarnitine-d3 hydrochloride

    		Isotope-Labeled Compounds Endogenous Metabolite Cardiovascular Disease Metabolic Disease Cancer
    Butyrylcarnitine-d3 hydrochloride is deuterium labeled Butyrylcarnitine (HY-113168). Butyrylcarnitine is an endogenous metabolite found in plasma. Elevated levels of Butyrylcarnitine are closely associated with abnormalities in lipid and energy metabolism. Butyrylcarnitine can serve as a diagnostic and prognostic indicator for certain diseases, such as heart failure and head and neck cancer .
    Butyrylcarnitine-d3 hydrochloride
  • HY-P991508
    Sym004

    		EGFR Cancer
    Sym004 is a 1:1 mixture of two recombinant, human-mouse chimeric mAbs directed against nonoverlapping EGFR epitopes (mAb992 and mAb1024). Sym004 is ability to mediate rapid EGFR internalization and subsequent degradation of internalized receptors via EGFR cross-linking. Sym004 can be used for the study of metastatic colorectal cancer, head and neck (H&N) and lung cancer .
    Sym004
  • HY-113168R
    Butyrylcarnitine (Standard)

    		Reference Standards Endogenous Metabolite Cardiovascular Disease Metabolic Disease Cancer
    Butyrylcarnitine (Standard) is the analytical standard of Butyrylcarnitine (HY-113168). This product is intended for research and analytical applications. Butyrylcarnitine is an endogenous metabolite found in plasma. Elevated levels of Butyrylcarnitine are closely associated with abnormalities in lipid and energy metabolism. Butyrylcarnitine can serve as a diagnostic and prognostic indicator for certain diseases, such as heart failure and head and neck cancer .
    Butyrylcarnitine (Standard)
  • HY-171450
    VMD-928

    		Trk Receptor Cancer
    VMD-928 is an orally active, allosteric, irreversible and selective tropomyosin receptor kinase A (TrkA) inhibitor. VMD-928 blocks the downstream signaling pathways triggered by the binding of nerve growth factor (NGF) to TrkA, thereby inhibiting cell proliferation, invasion, and promoting cancer cell death. VMD-928 is promising for research of various cancers, including prostate cancer, thymic carcinoma, mesothelioma, squamous cell carcinoma of the head and neck, squamous cell carcinoma of the lung, ovarian cancer, hepatocellular carcinoma .
    VMD-928
  • HY-132259
    Depatuxizumab mafodotin

    ABT-414

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Depatuxizumab mafodotin (ABT-414) is an antibody-drug conjugate (ADC). Depatuxizumab mafodotin specifically targets the epidermal growth factor receptor (EGFR). Depatuxizumab mafodotin can be used in the study of glioma, head and neck squamous cell carcinoma, non-small cell lung cancer, epidermoid carcinoma of the skin, and squamous cell carcinoma of the tongue .
    Depatuxizumab mafodotin
  • HY-106435
    Cystemustine

    		DNA/RNA Synthesis DNA Alkylator/Crosslinker Cancer
    Cystemustine is a DNA inhibitor (a chloroethyl nitrosourea, CENU). Cystemustine can cause DNA cross-linking, thereby inhibiting the proliferation of tumor cells. Cystemustine can also exert cytotoxic effects by interfering with the cell cycle, inducing cell re-differentiation, and altering phospholipid metabolism. Cystemustine exhibits high anti-tumor activity and a relatively short plasma half-life in mice. Cystemustine can be used for the study of various malignant tumors, including melanoma, glioma, renal cancer, head and neck cancer, and colorectal cancer, etc .
    Cystemustine
  • HY-13334
    BGT226 maleate
    5+ Cited Publications

    NVP-BGT226 maleate

    		 PI3K mTOR Autophagy Apoptosis Cancer
    BGT226 (NVP-BGT226 maleate) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ) /mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells .
    BGT226 maleate
  • HY-13334A
    BGT226
    5+ Cited Publications

    NVP-BGT226

    		 PI3K mTOR Autophagy Cancer
    BGT226 (NVP-BGT226) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ)/mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells .
    BGT226
  • HY-100218A
    RSL3
    Maximum Cited Publications
    378 Publications Verification

    (1S,3R)-RSL3

    		 p62 Glutathione Peroxidase Ferroptosis Reactive Oxygen Species (ROS) Cancer
    RSL3 ((1S,3R)-RSL3) is an inhibitor of glutathione peroxidase 4 (GPX4) (ferroptosis activator), reduces the expression of GPX4 protein, and induces ferroptotic death of head and neck cancer cell. RSL3 increases the expression of p62 and Nrf2 and inactivates Keap1 in HN3-rslR cells .
    RSL3
  • HY-175011
    EGFR-IN-165

    		EGFR Apoptosis Cancer
    EGFR-IN-165 is a potent EGFR inhibitor. EGFR-IN-165 demonstrates superior potency with IC50s of 17.18 and 64.74 nM against EGFR L858R/T790M and EGFR WT; 2.17 and 6.2 μM against NCI-H1975 cells and A431 cells. EGFR-IN-165 significantly inhibits the migration and induces G1 phase cell cycle arrest and cell apoptosis. EGFR-IN-165 can be used for the study of cancers such as non-small cell lung cancer, colorectal cancer, and head and neck squamous cell carcinoma .
    EGFR-IN-165
  • HY-134545
    N-Arachidonoyl-L-alanine
    1 Publications Verification

    NALA

    		 Reactive Oxygen Species (ROS) Cancer
    N-Arachidonoyl-L-alanine is an endocannabinoid analog with anti-cancer effects. N- Arachidonoyl-L-alanine kills HNSCC cells through 5-LO-mediated ROS productio .
    N-Arachidonoyl-L-alanine
  • HY-P99406A
    Petosemtamab (FUT8-KO)

    		EGFR Cancer
    Petosemtamab (FUT8-KO) is an anti-EGFR/LGR5 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Petosemtamab (HY-P99406) is an anti-EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to blockade of EGFR signaling and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the study of solid tumors such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC), etc .
    Petosemtamab (FUT8-KO)
  • HY-100218C
    (1R,3R)-RSL3
    2 Publications Verification

    		 Drug Isomer Ferroptosis Cancer
    (1R,3R)-RSL3 is an isomer of RSL3 (HY-100218A). RSL3 ((1S,3R)-RSL3) is an inhibitor of glutathione peroxidase 4 (GPX4) (ferroptosis activator), reduces the expression of GPX4 protein, and induces ferroptotic death of head and neck cancer cell. RSL3 increases the expression of p62 and Nrf2 and inactivates Keap1 in HN3-rslR cells .
    (1R,3R)-RSL3
  • HY-117548
    UNC1062
    2 Publications Verification

    		 TAM Receptor Apoptosis p38 MAPK ERK PI3K Akt JAK STAT Cardiovascular Disease Cancer
    UNC1062 is a highly selective tyrosine kinase (MERTK) inhibitor with an IC50 of 1.1 nM (Morrison Ki = 0.33 nM). UNC1062 exhibits good selectivity for the TAM family (TYRO3 IC50 = 60 nM, AXL IC50 = 85 nM). UNC1062 exhibits significant anti-proliferative effects and induces apoptosis in various cancer models (such as melanoma, gastric cancer, and acute myeloid leukemia). UNC1062 inhibits multiple pathways, including MAPK/ERK, PI3K/AKT and JAK/STAT and affects the motility of head and neck squamous cell carcinoma (HNSCC) cells through the RhoA signaling pathway. UNC1062 inhibits macrophage efferocytosis, and it suitable for research on atherosclerosis .
    UNC1062
  • HY-N0885
    Telocinobufagin
    1 Publications Verification

    Telobufotoxin; Telocinobufogenin

    		 JAK STAT mTOR PI3K Akt Polo-like Kinase (PLK) Na+/K+ ATPase Apoptosis Bacterial Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Telocinobufagin (Telobufotoxin; Telocinobufogenin) is an orally active bufadienolide with potential anti-tumor effects. Telocinobufagin exerts its anti-cancer effects on non-small cell carcinoma, osteosarcoma, thyroid cancer, breast cancer and head and neck squamous cell carcinoma by inhibiting the STAT3, JAK2/STAT3, LARP1-mTOR, PI3K/Akt/Snail and PLK1 pathways, and can also induce tumor cell apoptosis. Telocinobufagin enhances the Th1 immune response and protects against Salmonella typhimurium infection. Telocinobufagin has a strong cardiac-stimulating effect by inhibiting the activity of Na +/K +-ATPase, and it can promote renal fibrosis. Telocinobufagin demonstrates non-opioid analgesic effects in various acute pain models .
    Telocinobufagin
  • HY-P99141
    Anti-Mouse LAG-3 Antibody (C9B7W)

    		LAG-3 Inflammation/Immunology Cancer
    Anti-Mouse LAG-3 Antibody (C9B7W) is an anti-mouse LAG-3 IgG1 monoclonal antibody. Anti-Mouse LAG-3 Antibody (C9B7W) can enhance CD4 + T cell function and exert anti-tumor effects without blocking the interaction between LAG-3 and MHCII. Anti-Mouse LAG-3 Antibody (C9B7W) can be used for research on cancer such as head and neck squamous cell carcinoma (HNSCC) .
    Anti-Mouse LAG-3 Antibody (C9B7W)
  • HY-P990276
    Anti-Mouse CD317/BST2 Antibody (927)

    		Transmembrane Glycoprotein Infection Inflammation/Immunology Cancer
    Anti-Mouse CD317/BST2 Antibody (927) is a rat-derived IgG2b κ type antibody inhibitor, targeting to mouse CD317/BST2. Anti-Mouse CD317/BST2 Antibody (927) can deplete plasmacytoid dendritic cells (pDC). Anti-Mouse CD317/BST2 Antibody (927) can be used for the researches of cancer, infection, inflammation and immunology, such as head and neck squamous cell carcinoma (HNSCC), murine cytomegalovirus (MCMV) infection and asthma .
    Anti-Mouse CD317/BST2 Antibody (927)
  • HY-170595
    PROTAC LZK-IN-1

    		PROTACs MDM-2/p53 c-Myc MAP3K Cancer
    PROTAC LZK-IN-1 (Compound 21A) is a PROTAC that targets the degradation of LZK (Leucine Zipper Kinase, encoded by MAP3K13). PROTAC LZK-IN-1 (10 μM) promotes the degradation of LZK and inhibits the expression of p53 and c-MYC, leading to reduced viability of global head and neck squamous cell carcinoma (HNSCC) cell lines. PROTAC LZK-IN-1 can be used in cancer research. PROTAC LZK-IN-1 consists of an E3 ligase ligand (blue part, HY-112078), a target protein ligand (red part, HY-170596), and a linker (black part, HY-W019543)[1].
    PROTAC LZK-IN-1
  • HY-B1260
    Cetrimonium bromide
    2 Publications Verification

    CTAB; Cetyltrimethylammonium bromide; Hexadecyltrimethylammonium bromide

    		 Biochemical Assay Reagents MMP Apoptosis TGF-β Receptor Cancer
    Cetrimonium bromide (CTAB), a quaternary ammonium, is an orally active cationic surfaetant. Cetrimonium bromide has toxicity and anticancer effect. Cetrimonium bromide inhibits cell migration and invasion through modulating the canonical and non-canonical TGF-β signaling pathways. Cetrimonium bromide can be used for DNA extraction .
    Cetrimonium bromide
  • HY-P2076
    Dusquetide

    SGX942

    		 p62 Bacterial Infection Cancer
    Dusquetide (SGX942) is a first-in-class innate defense regulator (IDR). Dusquetide modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide shows activity in both reducing inflammation and increasing clearance of bacterial infection . DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns
    Dusquetide
  • HY-114245R
    Se-Methylselenocysteine (Standard)

    Methylselenocysteine (Standard); Se-Methylseleno-L-cysteine (Standard)

    		 Reference Standards Apoptosis Endogenous Metabolite Beta-secretase Cancer
    Risedronic acid (Standard) is the analytical standard of Risedronic acid. This product is intended for research and analytical applications. 0
    Se-Methylselenocysteine (Standard)
  • HY-122502
    Pyrazofurin
    1 Publications Verification

    Pirazofurin

    		 DNA/RNA Synthesis Antibiotic Influenza Virus HIV SARS-CoV Infection Cancer
    Pyrazofurin is an antitumor pyrimidine nucleoside analogue and a orotate-phosphoribosyltransferase inhibitor. Pyrazofurin inhibits cell proliferation and intracellular DNA synthesis by inhibiting uridine 5'-phosphate synthase. Pyrazofurin is also an antibiotic with a broad spectrum of antiviral activity .
    Pyrazofurin
  • HY-114245B
    Se-Methylselenocysteine hydrochloride

    Methylselenocysteine hydrochloride; Se-Methylseleno-L-cysteine hydrochloride

    		 Endogenous Metabolite Apoptosis Beta-secretase Cancer
    Se-Methylselenocysteine hydrochloride, a precursor of Methylselenol, has potent cancer chemopreventive activity and anti-oxidant activity. Se-Methylselenocysteine hydrochloride is orally bioavailable, and induces apoptosis .
    Se-Methylselenocysteine hydrochloride
  • HY-P2076A
    Dusquetide TFA

    SGX942 TFA

    		 p62 Bacterial Infection Cancer
    Dusquetide (SGX942) TFA is a first-in-class innate defense regulator (IDR). Dusquetide TFA modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide TFA shows activity in both reducing inflammation and increasing clearance of bacterial infection . DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns
    Dusquetide TFA
  • HY-114245
    Se-Methylselenocysteine
    2 Publications Verification

    Methylselenocysteine; Se-Methylseleno-L-cysteine

    		 Apoptosis Endogenous Metabolite Beta-secretase Cancer
    Se-Methylselenocysteine, a precursor of Methylselenol, has potent cancer chemopreventive activity and anti-oxidant activity. Se-Methylselenocysteine is orally bioavailable, and induces apoptosis .
    Se-Methylselenocysteine
  • HY-P99032
    Monalizumab
    3 Publications Verification

    IPH2201

    		 Checkpoint Kinase (Chk) IFNAR Inflammation/Immunology Cancer
    Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) .
    Monalizumab
  • HY-174803
    WMJ-J-09

    		p38 MAPK HDAC AMPK MDM-2/p53 Microtubule/Tubulin Pim Survivin Apoptosis Cancer
    WMJ-J-09 is an HDAC inhibitor with IC50 values of 7.5 nM (HDAC1), 21.3 nM (HDAC2), 18.4 nM (HDAC3), 90.9 nM (HDAC8), 3.9 nM (HDAC6) and 8715.7 nM (HDAC4). WMJ-J-09 blocks the cell cycle and induces apoptosis in cancer cells. WMJ-J-09 induces cancer cell death through the LKB1-AMPK-p38MAPK-p63-survivin signaling cascade.WMJ-J-09 inhibits HDAC enzyme activity, leading to acetylation of key proteins and thereby regulating cancer cell death. WMJ-J-09 can be used in HCT116 cells and FaDu cells research[1][2].
    WMJ-J-09

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: